# Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer

## Media Release

**Copenhagen, Denmark, August 21, 2019**

**Genmab A/S (Nasdaq: GMAB) announced today that preliminary data from the Phase I/II trial of enapotamab vedotin in advanced non-small cell lung cancer (NSCLC) has been accepted for oral presentation at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer (IASLC 2019 WCLC) taking place from September 7-10, 2019 in Barcelona, Spain.** Meeting abstracts are currently accessible form the IASLC 2019 WCLC website, https://wclc2019.iaslc.org/.

“We are honored that early data from enapotamab vedotin was chosen for oral presentation at the IASLC 2019 WCLC. The selection of this data for presentation also supports our belief in the potential of this first-in-class compound for patients with advanced non-small cell lung cancer progressing on chemotherapy and a checkpoint inhibitor; we look forward to more advanced and complete data becoming available in the future” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

**Enapotamab vedotin abstract to be presented:**
First-in-human Phase 1/2 trial of anti-AXL antibody–drug conjugate enapotamab vedotin in advanced NSCLC – Oral presentation, Sunday, September 8, 2019, 11:15 AM – 11:25 AM CEST. Full abstract available here.

**About Genmab**
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with core sites in Utrecht, the Netherlands and Princeton, New Jersey, U.S.

**Contact:**
Marisol Peron, Corporate Vice President, Communications & Investor Relations
T: +1 609 524 0065; E: mmp@genmab.com

**For Investor Relations:**
Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com

*This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to*

# Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer

*differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's final prospectus for our U.S. public offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.*